Valproic Acid, an Antiepileptic Drug with Histone Deacetylase Inhibitory Activity, Potentiates the Cytotoxic Effect of Apo2L/TRAIL on Cultured Thoracic Cancer Cells through Mitochondria-Dependent Caspase Activation

• Published in: Neoplasia (New York, N.Y.) Vol. 8; no. 6; pp. 446 - 457
• Main Authors: Ziauddin, M. Firdos, Yeow, Wen-Shuz, Maxhimer, Justin B., Baras, Aris, Chua, Alex, Reddy, Rishindra M., Tsai, Wilson, Cole, George W., Schrump, David S., Nguyen, Dao M.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2006; Elsevier
• Subjects: Apo2L/TRAIL; Apoptosis; Apoptosis Regulatory Proteins - metabolism; BcI2; Carcinoma, Non-Small-Cell Lung - drug therapy; caspases; Caspases - metabolism; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Activation; Enzyme Inhibitors - pharmacology; Epilepsy - drug therapy; esophageal cancer; Histone deacetylase inhibitor; Histone Deacetylase Inhibitors; Humans; lung cancer; Lung Neoplasms - drug therapy; malignant pleural mesothelioma; Membrane Glycoproteins - metabolism; mitochondria; Mitochondria - enzymology; Thoracic Neoplasms - drug therapy; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha - metabolism; Valproic Acid - pharmacology; malignant pleural mesothelioma; SMAC/DIABLO; esophageal cancer; TRAIL; NSCLC; mitochondria; MPM; VA; MTT; lung cancer; GFP; Histone deacetylase inhibitor; TUNEL; EsC; BcI2; Apo2L/TRAIL; caspases; HDACI
• DOI: 10.1593/neo.05823
• ISSN: 1476-5586

Inhibitors of histone deacetylases have been shown to enhance the sensitivity of cancer cells to tumor necrosis factor-related apoptosis-inducing ligand TRAIL-mediated cytotoxicity. Valproic acid (VA), a commonly used antiepileptic agent whose pharmacokinetics and toxicity profiles are well described, is a histone deacetylase inhibitor. This project aims to evaluate if VA can potentiate Apo2L/TRAIL-mediated cytotoxicity in cultured thoracic cancer cells and to elucidate the underlying molecular mechanism responsible for this effect. VA sensitized cultured thoracic cancer cells to Apo2L/TRAIL, as indicated by a 4-fold to a >20-fold reduction of Apo2L/TRAIL IC50 values in combination-treated cells. Although VA (0.5–5 mM) or Apo2L/TRAIL (20 ng/ml) induced less than 20% cell death, VA + Apo2L/TRAIL combinations caused 60% to 90% apoptosis of cancer cells. Moreover, substantial activation of caspases 8, 9, and 3, which was observed only in cells treated with the drug combinations, was completely suppressed by BcI2 overexpression or by the caspase 9 inhibitor. Both the caspase 9 inhibitor and BcI2 completely abrogated the substantial cytotoxicity and apoptosis induced by this combination, thus highlighting the pivotal role of the type II pathway in this process. These findings provide a rationale for the development of VA and Apo2L/TRAIL combination as a novel molecular therapeutic regimen for thoracic cancers.